Key result
Iodixanol reduces contrast-induced nephropathy ~59% vs. ioxaglate in renal impairment.
Why the study?
Does iodixanol reduce the incidence of contrast-induced nephropathy compared to ioxaglate in adults with renal impairment undergoing coronary angiography?
Population
300 adults with renal impairment undergoing coronary angiography with or without percutaneous coronary…
Comparison
Iodixanol (an iso-osmolar contrast medium) vs Ioxaglate (a low-osmolar contrast medium)
Design
RCT, randomized
Authors
Loading...
In patients with renal impairment undergoing coronary angiography, the iso-osmolar contrast medium iodixanol significantly reduces the risk of contrast-induced nephropathy compared to the low-osmolar contrast medium ioxaglate.
RCT (n=300)
randomized
Does iodixanol reduce the incidence of contrast-induced nephropathy compared to ioxaglate in adults with renal impairment undergoing coronary angiography?
Odds Ratio: 0.415 (95% CI 0.194–0.889)
Absolute Event Rate: 7.9% vs 17%
p-value: p=0.021
In patients with renal impairment undergoing coronary angiography, the iso-osmolar contrast medium iodixanol significantly reduces the risk of contrast-induced nephropathy compared to the low-osmolar contrast medium ioxaglate.
Jo et al. (2006) conducted an RCT in renal impairment undergoing coronary angiography (n=300). Iodixanol vs. Ioxaglate was evaluated on incidence of contrast-induced nephropathy (CIN) (an increase in serum creatinine [SCr] ≥25% or ≥0.5 mg/dl) (OR 0.415, 95% CI 0.194 to 0.889, p=0.021). Iodixanol significantly reduced the incidence of contrast-induced nephropathy compared to ioxaglate (7.9% vs 17.0%; OR 0.415; 95% CI 0.194-0.889; p=0.021) in patients with renal impairment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: